Global pharmaceutical major Lupin Limited has been awarded the prestigious Great Place To Work® certification for 2026-27, positioning itself among select pharmaceutical companies to achieve this globally recognized workplace excellence standard. The certification was announced on April 07, 2026, following a comprehensive evaluation spanning all of Lupin's subsidiaries and geographical locations.

Recognition Through Employee Engagement

The Great Place To Work® certification, widely regarded as the gold standard for workplace excellence, was earned through significant employee participation and feedback. The evaluation process demonstrated strong workforce engagement across Lupin's global operations.

Leadership Perspective on Workplace Culture

Yashwant Mahadik, President – Global Human Resources at Lupin, emphasized the significance of this achievement in reflecting the company's inclusive and values-driven workplace culture. The recognition highlights how employees across different geographies feel respected, valued, and empowered to perform at their best. The company remains committed to continuously enhancing the employee experience across all locations while further strengthening its organizational culture.

Investment in Human Capital

Lupin's commitment to its workforce is demonstrated through substantial investments in employee development and benefits. The company maintains a permanent workforce of over 24,000 professionals across various functions and geographical locations.

Global Pharmaceutical Presence

Lupin Limited operates as a global pharmaceutical leader headquartered in Mumbai, India, with products distributed across over 100 markets worldwide. The company specializes in pharmaceutical products including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Lupin maintains a strong market position in India and the United States across multiple therapy areas including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health.

The company's operational infrastructure includes 15 state-of-the-art manufacturing sites and 7 research centers globally. Through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions – the organization remains committed to improving patient health outcomes while maintaining its focus on workplace excellence and employee satisfaction.

Lupin Limited has submitted its quarterly compliance certificate to the National Stock Exchange of India Limited and BSE Limited in accordance with regulatory requirements for the quarter ended March 31, 2026.

Regulatory Compliance Submission

The pharmaceutical company filed the certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The submission was made on April 6, 2026, by Company Secretary and Compliance Officer Amit Kumar Gupta.

Certificate Details

The compliance certificate was issued by MUFG Intime India Private Limited (formerly Link Intime India Private Limited), which serves as the company's Registrar and Share Transfer Agent. The certificate, dated April 3, 2026, was signed by Ashok Shetty, Sr. Vice President-Corporate Registry.

Confirmation of Compliance

MUFG Intime India Private Limited confirmed several key compliance aspects in their certificate:

• Securities received from depository participants for dematerialization during the quarter were properly confirmed to the depositories
• All securities comprised in the certificates have been listed on stock exchanges where previously issued securities are listed
• Security certificates received for dematerialization were confirmed or rejected within prescribed timelines
• Received certificates were mutilated and cancelled after due verification by the depository participant
• Names of depositories have been substituted in the register of members as registered owners

Corporate Information

This quarterly submission represents standard regulatory compliance for publicly listed companies to ensure transparency and proper handling of share transfer and dematerialization processes. The certificate confirms that all regulatory requirements were met during the specified quarter period.